Ghrelin and Brain Stimulation Modulate Stomach Signals in Chemo-Treated Rats
Background
Cisplatin, a potent chemotherapy drug, is notorious for inducing severe nausea and vomiting (CINV), significantly impacting patient quality of life and treatment adherence. These debilitating gastrointestinal side effects are often linked to dysregulation of visceral sensory pathways. The lateral hypothalamus area (LHA) and the dorsal vagal complex (DVC) are critical brain regions involved in appetite regulation, gastric motility, and processing visceral sensory information. Ghrelin, a "hunger hormone," also plays a role in modulating gut-brain axis communication. Despite their known individual roles, the precise interplay between ghrelin, LHA activity, and DVC-mediated gastric sensory neuron responses in the context of cisplatin-induced dysfunction remains poorly understood.
Results
In cisplatin-treated rats, baseline activity of gastric distention neurons was significantly elevated compared to healthy controls, showing a 2.3-fold increase in discharge frequency (p<0.01). Specifically, the firing rate increased from 5.4 ± 0.6 Hz in controls to 12.5 ± 1.2 Hz in cisplatin-treated animals. This hyperactive state was markedly altered by interventions. Both Ghrelin administration and LHA electrical stimulation significantly attenuated this heightened neuronal activity, reducing discharge frequency by 43% and 38% respectively (p<0.001 for both). Ghrelin reduced the firing rate from 12.5 ± 1.2 Hz to 7.1 ± 0.8 Hz, while LHA stimulation decreased it to 7.8 ± 0.9 Hz. Further experiments revealed that these modulatory effects were abolished by local microinjection of a ghrelin receptor antagonist into the DVC, confirming the DVC's crucial role in mediating these responses. The study also observed a significant correlation (r=0.75, p<0.001) between ghrelin levels and neuronal activity modulation.
Why It Matters
This study provides compelling evidence that both Ghrelin and LHA electrical stimulation can effectively normalize the pathological hyperactivity of gastric distention neurons in a cisplatin-induced gastric dysfunction model. This suggests a novel neuro-modulatory pathway involving the DVC that could be leveraged to counteract the debilitating gastrointestinal side effects of chemotherapy. The findings highlight the potential for developing new therapeutic strategies targeting the ghrelin system or specific brain regions to alleviate chemotherapy-induced nausea and vomiting (CINV). Future research should focus on translating these findings into human trials, potentially exploring ghrelin mimetics or non-invasive brain stimulation techniques to improve patient outcomes.